Clinical Trials Browser

Phase 2 × Neoplasms, Plasma Cell × fludarabine × Clear all

NCT01810588 2025-09-02

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Phase 2 Active not recruiting

270 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Phase 2 Completed

117 enrolled 27 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Paraproteinemias, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT01131169 2021-12-02

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Phase 2 Completed

66 enrolled 13 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00303719 2020-05-12

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Phase 2 Terminated

342 enrolled 14 charts

GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Kidney Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT00948922 2019-09-18

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Phase 2 Completed

124 enrolled 13 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00800839 2016-09-19

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Phase 2 Completed

56 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hematologic Diseases, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT01518153 2016-03-17

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Phase 2 Terminated

16 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT01500161 2013-11-25

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Phase 2 Terminated

1 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00382694 2006-09-29

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Phase 2 Unknown

80 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell